The effects of somatostatin and SMS 201-995 on experimentally-induced pancreatitis and endotoxaemia in rats and on monocyte activity in patients with cirrhosis and portal hypertension.
D000818:Animals; D001427:Bacterial Toxins / Q000037:antagonists & inhibitors; D002470:Cell Survival / Q000187:drug effects; D004731:Endotoxins / Q000037:antagonists & inhibitors; D006801:Humans; D066298:In Vitro Techniques; D007674:Kidney Diseases / Q000473:pathology / Q000517:prevention & control*; D008103:Liver Cirrhosis / Q000503:physiopathology; D008107:Liver Diseases / Q000473:pathology / Q000517:prevention & control*; D009000:Monocytes / Q000166:cytology / Q000502:physiology*; D015282:Octreotide; D010195:Pancreatitis / Q000517:prevention & control*; D010587:Phagocytosis; D051381:Rats; D013004:Somatostatin / Q000031:analogs & derivatives* / Q000627:therapeutic use*
D001427:Bacterial Toxins; D004731:Endotoxins; D013004:Somatostatin; D015282:Octreotide